NXGL

NexGel, Inc. (NXGL) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This summary covers NexGel, Inc.'s unaudited financial results for the quarterly and six-month periods ended June 30, 2024. NexGel manufactures high water content hydrogels for wound care, medical diagnostics, and cosmetics. The company operates through two primary segments: the NexGel segment (manufacturing, branded consumer products, and recent acquisitions) and the CGN JV segment (converting and packaging). The company is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. YTD figures represent the six months ended June 30.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 23.4% in Q2 and 51.5% YTD compared to the prior year. This growth was driven primarily by the Branded Consumer Products line, specifically the inclusion of the "Silly George" beauty brand (acquired May 2024) and "Kenkoderm" skincare line (acquired Dec 2023).
• Margin Expansion: Gross margin improved significantly from 15.0% to 28.5% in Q2, attributed to the higher-margin mix of branded consumer products.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 57.4% in Q2 and 50.9% YTD. Key drivers included a 166.3% increase in advertising and Amazon fees to support new brands, and a 63.0% increase in professional and consulting fees.
• Acquisition Activity: The company acquired the "Silly George" business for $400,000 cash and $200,000 in stock in May 2024. This contributed $380,000 in revenue in the first month of ownership.
• Capital Structure: In February 2024, the company completed a Registered Direct Offering (RDO) raising approximately $0.95 million net. In August 2024 (subsequent event), the company announced another RDO expected to raise ~$1.11 million.

Outlook, Risks, and Management Commentary

• Going Concern: Management states they have sufficient capital to operate into 2025 due to recent capital raises. However, the company expects to continue incurring losses in the near term. Long-term viability depends on achieving profitable operations and potentially raising additional capital.
• Strategic Focus: The company is expanding into adjacent industries (cosmetics, athletic products) and developing proprietary medical devices. They are actively building a sales pipeline for contract manufacturing and branded products.
• Risks: Key risks include the ability to raise sufficient capital, dependence on a small group of customers (one customer represented 15% of YTD revenue), and the uncertainty of new product launches. The company also faces risks related to the integration of recent acquisitions.
• Subsequent Events: On August 8, 2024, the company entered into agreements for a new RDO of 222,000 units at $5.00 per unit, expected to close around August 14, 2024.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.07 million cash balance against the $1.79 million operating cash burn rate for the first half of the year.
• Customer Concentration: Review the dependency on the top customer (15% of YTD revenue) and the impact of potential loss of this client.
• Acquisition Integration: Assess the performance of the "Silly George" and "Kenkoderm" brands post-acquisition to ensure they meet revenue and margin projections.
• Capital Needs: Monitor the closing and terms of the August 2024 RDO and evaluate if further equity or debt financing will be required to fund operations through 2025.
• Warrant Liability: Note the $176,000 warrant liability on the balance sheet and its potential impact on future dilution or cash flow if exercised.